---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028531"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:00:22.101726+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics appoints Alessandro Riva to board, names Felix Baker chairman, promotes Eric Westin to CMO

## Summary
- Pierre Legault and Richard Kender to retire from board after AGM June 17, 2025; Felix Baker to become chairman.
- Alessandro Riva joins board and scientific committee; receives annual cash $60k, option 25k shares, RSU 12.5k shares vesting over 3 years.
- CDO Santiago Arroyo resigned March 24; separation includes pro-rated 2025 bonus, COBRA to May 2025; consulting fee $12k/yr, equity continues vesting.
- Eric Westin promoted to CMO; Jim MacDonald-Clink promoted to SVP head of business development.

## SEC filing metadata
- accession: 0001104659-25-028531
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/tm2510464d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028531
- JSON: https://secwatch.observer/filing/0001104659-25-028531.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028531.txt

## Key facts
- Executive change
  Pierre Legault resigned as Director at BICYCLE THERAPEUTICS PLC.
  - Action: resigned
  - Role: Director
  source text: On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm
- Executive change
  Santiago Arroyo resigned as Chief Development Officer at BICYCLE THERAPEUTICS PLC.
  - Action: resigned
  - Role: Chief Development Officer
  source text: Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm
- Executive change
  Richard Kender resigned as Director at BICYCLE THERAPEUTICS PLC.
  - Action: resigned
  - Role: Director
  source text: On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm
- Executive change
  Alessandro Riva was appointed as Director at BICYCLE THERAPEUTICS PLC.
  - Action: appointed
  - Role: Director
  source text: appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465925028531/0001104659-25-028531-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.